Diabetes Care:应用ADA糖尿病新定义或可改善心血管风险分层

2011-09-15 MedSci原创 MedSci原创

　　德国学者的一项研究表明，在接受冠脉造影的人群中，应用美国糖尿病学会（ADA）2010版糖尿病定义有可能改善心血管风险分层。论文于2011年9月12日在线发表于《糖尿病护理》（Diabetes Care）。　　此项研究共纳入2002例既往无糖尿病病史的受试者。研究者对依据ADA 2010版糖尿病定义可诊断为新发2型糖尿病，但依据ADA 2009版定义则未伴糖尿病

　　德国学者的一项研究表明，在接受冠脉造影的人群中，应用美国糖尿病学会（ADA）2010版糖尿病定义有可能改善心血管风险分层。论文于2011年9月12日在线发表于《糖尿病护理》（Diabetes Care）。

　　此项研究共纳入2002例既往无糖尿病病史的受试者。研究者对依据ADA 2010版糖尿病定义可诊断为新发2型糖尿病，但依据ADA 2009版定义则未伴糖尿病的受试者进行了预后评估。平均随访时间为7.7年。

　　结果显示，随访期间共有346例受试者死亡（202例心血管性死亡）。与依据ADA 2010版定义未被诊断为2型糖尿病的受试者相比，依据 2009版定义诊断为糖尿病的受试者全因死亡率和心血管死亡率显著升高（P均≤ 0.003）。对于依据ADA 2010版定义可诊断为2型糖尿病但依据 2009版定义无糖尿病的受试者而言，其心血管疾病死亡风险显著升高（P=0.029）。

　　链接：

　　 Additional Use of Glycated Hemoglobin for Diagnosis of Type 2 Diabetes in People Undergoing Coronary Angiography Reveals a Subgroup at Increased Cardiovascular Risk

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1759103, encodeId=177c1e5910389, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 23 22:03:00 CST 2011, time=2011-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636462, encodeId=cefc16364627c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 26 13:03:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082316, encodeId=a610208231665, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jul 03 17:03:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900916, encodeId=f278190091652, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Nov 06 02:03:00 CST 2011, time=2011-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949287, encodeId=2cfe194928e30, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Sep 16 07:03:00 CST 2011, time=2011-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264435, encodeId=883c126443573, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360950, encodeId=7e8d136095056, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=)]
2011-09-23 ms5439512287675881

#BET#

26 0
[GetPortalCommentsPageByObjectIdResponse(id=1759103, encodeId=177c1e5910389, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 23 22:03:00 CST 2011, time=2011-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636462, encodeId=cefc16364627c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 26 13:03:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082316, encodeId=a610208231665, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jul 03 17:03:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900916, encodeId=f278190091652, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Nov 06 02:03:00 CST 2011, time=2011-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949287, encodeId=2cfe194928e30, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Sep 16 07:03:00 CST 2011, time=2011-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264435, encodeId=883c126443573, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360950, encodeId=7e8d136095056, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=)]
2012-08-26 ms9608593228839890

#DIA#

37 0
[GetPortalCommentsPageByObjectIdResponse(id=1759103, encodeId=177c1e5910389, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 23 22:03:00 CST 2011, time=2011-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636462, encodeId=cefc16364627c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 26 13:03:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082316, encodeId=a610208231665, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jul 03 17:03:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900916, encodeId=f278190091652, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Nov 06 02:03:00 CST 2011, time=2011-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949287, encodeId=2cfe194928e30, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Sep 16 07:03:00 CST 2011, time=2011-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264435, encodeId=883c126443573, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360950, encodeId=7e8d136095056, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=)]
2012-07-03 ms5353107019656438

#血管风险#

33 0
[GetPortalCommentsPageByObjectIdResponse(id=1759103, encodeId=177c1e5910389, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 23 22:03:00 CST 2011, time=2011-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636462, encodeId=cefc16364627c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 26 13:03:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082316, encodeId=a610208231665, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jul 03 17:03:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900916, encodeId=f278190091652, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Nov 06 02:03:00 CST 2011, time=2011-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949287, encodeId=2cfe194928e30, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Sep 16 07:03:00 CST 2011, time=2011-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264435, encodeId=883c126443573, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360950, encodeId=7e8d136095056, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=)]
2011-11-06 木头人513

#Diabetes#

29 0
[GetPortalCommentsPageByObjectIdResponse(id=1759103, encodeId=177c1e5910389, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 23 22:03:00 CST 2011, time=2011-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636462, encodeId=cefc16364627c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 26 13:03:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082316, encodeId=a610208231665, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jul 03 17:03:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900916, encodeId=f278190091652, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Nov 06 02:03:00 CST 2011, time=2011-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949287, encodeId=2cfe194928e30, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Sep 16 07:03:00 CST 2011, time=2011-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264435, encodeId=883c126443573, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360950, encodeId=7e8d136095056, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=)]
2011-09-16 hukaixun

#新定义#

26 0
[GetPortalCommentsPageByObjectIdResponse(id=1759103, encodeId=177c1e5910389, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 23 22:03:00 CST 2011, time=2011-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636462, encodeId=cefc16364627c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 26 13:03:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082316, encodeId=a610208231665, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jul 03 17:03:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900916, encodeId=f278190091652, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Nov 06 02:03:00 CST 2011, time=2011-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949287, encodeId=2cfe194928e30, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Sep 16 07:03:00 CST 2011, time=2011-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264435, encodeId=883c126443573, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360950, encodeId=7e8d136095056, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=)]
2011-09-17 般若傻瓜

#ADA#

34 0
[GetPortalCommentsPageByObjectIdResponse(id=1759103, encodeId=177c1e5910389, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 23 22:03:00 CST 2011, time=2011-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636462, encodeId=cefc16364627c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 26 13:03:00 CST 2012, time=2012-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082316, encodeId=a610208231665, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jul 03 17:03:00 CST 2012, time=2012-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900916, encodeId=f278190091652, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Nov 06 02:03:00 CST 2011, time=2011-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949287, encodeId=2cfe194928e30, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Sep 16 07:03:00 CST 2011, time=2011-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264435, encodeId=883c126443573, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360950, encodeId=7e8d136095056, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Sep 17 08:03:00 CST 2011, time=2011-09-17, status=1, ipAttribution=)]
2011-09-17 oliver169

#风险分层#

30 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

内分泌科

Diabetes Care:应用ADA糖尿病新定义或可改善心血管风险分层

相关资讯

科室

工具

服务